Skanditek’s subsidiary CMA Microdialysis AB to implement new share issue totaling SEK 70 million
The Skanditek subsidiary CMA is implementing a private placement of new shares amounting to SEK 56 million. The new issue will be directed at Investor Growth Capital. Within a period of three years, CMA’s Board of Directors will have an opportunity to arrange an additional private placement aimed at Investor Growth Capital in an amount of SEK 14 million.
For further information, see the appended press release from CMA Microdialysis AB or visit www.microdialysis.se
CMA will hold an Extraordinary General Meeting on Thursday, October 16, 2008.
Prior to the private placement, Skanditek’s shareholding in CMA amounts to 77.95 percent. Following implementation of the private placement, amounting to SEK 56 million, Skanditek’s shareholding in CMA will be reduced to 49.93 percent and CMA will thus switch from being a Skanditek subsidiary to an associated company.
Stockholm, September 16, 2008
SKANDITEK INDUSTRIFÖRVALTNING AB (publ)
For further information, please contact:
Patrik Tigerschiöld, President and CEO,
telephone: +46-(0)8-614 00 20; e-mail: patrik.tigerschiold@skanditek.semailto:patrik.tigerschiold@skanditek.se
SKANDITEK is an industrial holding company with investments in Swedish companies. The business concept is to generate sustainable and healthy value growth by means of industrial management of operational companies. The portfolio comprises nine investments in the electronics, bio/medical technology and services sectors. The principal holdings are Bure Equity, MYDATA automation, PartnerTech, Vitrolife and CMA. Skanditek is listed on the OMX Nordic Exchange.
Stockholm, September 16, 2008
CMA Microdialysis raises SEK 70 million in growth capital
CMA Microdialysis AB (“CMA”), a leading Swedish medical device company, accelerates its growth agenda by raising SEK 70 million (approx USD 10.4 million) from Investor Growth Capital.
CMA is the pioneer and leader within organ diagnostics and tissue chemistry monitoring. The company’s medical devices are used in intensive care across the globe to monitor biochemical processes in individual organs such as the brain, liver and abdomen. The unique technology provides opportunities to detect changes in organ chemistry, thereby predicting the onset of complications and disease processes. The company was founded in 1984.
In response to the demands of modern intensive care for real-time and more efficient blood glucose monitors, CMA was awarded a large grant from VINNOVA (Swedish Governmental Agency for Innovation Systems) in 2007. The grant, in combination with dedicated support from the major shareholder Skanditek Industriförvaltning AB, has enabled the development of a new technical platform offering the opportunity for real-time monitoring of blood glucose and other metabolic markers.
“The aim of the growth capital is to accelerate our efforts to develop a new real-time system for monitoring metabolic markers, including blood glucose. Our vision is to offer real-time solutions that can streamline the many manual routines of modern intensive care by delivering quicker and more accurate clinical decisions.” says Philip Siberg, President and CEO of CMA.
Through a new shares issue, Investor Growth Capital, a subsidiary of Investor AB, is initially investing SEK 56 million (approx USD 8.3 million) in CMA. The board of CMA has the right to call for an additional SEK 14 million (approx USD 2.1 million) from IGC within three years. IGC will become the second largest shareholder following Skanditek Industriförvaltning AB.
The aim of the growth capital is to accelerate CMA’s growth plans and to prepare for a future international roll-out of the company’s new technology platform. As a part of the intensified growth agenda, CMA will simultaneously invest SEK 27.5 million (approx USD 4.1 million) in the affiliate company, Dipylon Medical AB.
For more information, please contact:
Philip Siberg, CEO
CMA Microdialysis AB
Tel: +46-(0)70 790 6734
psi@microdialysis.se
About CMA Microdialysis AB
CMA Microdialysis is the leading company devoted to the development, manufacturing and marketing of the Microdialysis technique. The company was formed in 1984 and was the first company in the world to market Microdialysis products and know-how. Consumables, instruments and computer software are sold to universities, hospitals and pharmaceutical companies as unique tools for in vivo sampling and diagnostics of organs and tissues. CMA has offices in Sweden, the US and Germany, as well as distributors covering more than 40 countries. For more information, see www.microdialysis.com